Prostate Cancer

United States sees the biggest drop in prostate cancer rate

Prostate cancer incidence and mortality rates are decreasing or stabilizing in most parts of the world, with the United States recording the biggest drop in incidence, according to results presented at the AACR Annual Meeting 2019, March 29-April 3. Despite the trend toward declining or stabilizing rates, prostate cancer remains the second most commonly diagnosed cancer and the sixth leading cause of cancer death among men worldwide, said the study's lead author, MaryBeth Freeman, MPH, senior associate scientist, Surveillance Research, at the American Cancer Society in Atlanta. "Previous studies have indicated significant variation in prostate cancer rates, due to factors including detection practices, availability of treatment, and genetic factors," Freeman said. "By comparing rates from different countries, we can assess differences in detection practices [...]

2019-04-09T08:34:29-07:00April 9th, 2019|

Prostate cancer cells change the behavior of healthy cells

Prostate cancer cells change the behavior of other cells around them, including normal cells, by 'spitting out' a protein from their nucleus, new research has found. The tiny pieces of protein are taken up by the other cells, provoking changes that promote tumor growth and -- the researchers believe -- help the cancer hide from the body's immune system. The process has been captured for the first time on video (https://youtu.be/Ye4t9IJpRdo) by researchers at the University of Bradford and University of Surrey. The research is published today [26 March] in Scientific Reports. Lead researcher, Professor Richard Morgan from the University of Bradford, said: "For tumors to survive, grow bigger and spread they need to control the behavior of cancer cells and the normal cells [...]

2019-04-02T10:05:10-07:00April 2nd, 2019|

Empower Yourself With Prostate Cancer Facts

What are the symptoms of prostate cancer? Early prostate cancer usually causes no symptoms. Men who have prostate cancer can be symptom-free for years. But as it grows, prostate cancer can cause some symptoms. Men should see a health care provider if they: Have to urinate often, especially at night Have trouble starting or stopping urine flow Have a weak or slow urine flow Have blood in the urine or semen Feel frequent pain or stiffness in the lower back, hips, or ribs Conditions other than prostate cancer could cause these symptoms. But the only way to know what’s causing them is to see a health care provider. HIFU Prostate Cancer Facts What do you need to know about the American Cancer Society® prostate [...]

2019-03-26T12:17:00-07:00March 26th, 2019|

Compounds in coffee may inhibit the growth of prostate cancer

For the first time, scientists have identified compounds found in coffee which may inhibit the growth of prostate cancer. This is a pilot study, carried out on drug-resistant cancer cells in cell culture and in a mouse model; it has not yet been tested in humans. This work is presented at the European Association of Urology congress in Barcelona, after publication in the peer-reviewed journal The Prostate. Coffee is a complex mixture of compounds which has been shown to influence human health in both positive and negative ways. There is increasing evidence that drinking certain types of coffee is associated with a reduction in incidence of some cancers, including prostate cancers. Now Japanese scientists have studied the effects of two compounds found in coffee, [...]

2019-03-19T08:36:47-07:00March 19th, 2019|

No obvious benefits for prostate cancer patients using low-dose aspirin

Low-dose aspirin use does not seem to reduce the overall risk for prostate cancer death at the population level. However, results for extended exposure periods suggest that low-dose aspirin might be inversely associated with prostate cancer mortality after 5 years from cancer diagnosis. Findings from a nationwide cohort study are published in Annals of Internal Medicine. Recent studies suggest that aspirin use may improve survival in patients with prostate cancer, but study results are inconclusive. Researchers from the Danish Cancer Society Research Center, Aarhus University Hospital, Copenhagen University Hospital, and University of Southern Denmark used nationwide registries in Denmark to assess the association between postdiagnosis use of low-dose aspirin and prostate cancer mortality. Their analysis did not find convincing evidence of an overall protective [...]

2019-03-05T11:54:54-08:00March 5th, 2019|

HIFU Patients Urged to Advocate for Reimbursements

Advocating for HIFU Reimbursement Men who may have benefited from HIFU for Prostate Cancer are being asked to help more men receive this life-saving procedure. HIFU Prostate Services and California HIFU is asking past-patients to help newly diagnosed men have a greater opportunity to receive HIFU for prostate cancer by advocating for higher Medicare reimbursement for HIFU. The steps have been outlined below to help with this process, along with tips for being as effective as possible. Finding Your Representatives Click here to search the House of Representatives Click here to search for your Senators Write a Letter to Your Representatives in Congress Now that you have found your representatives in Congress and the Senate, one of the easiest ways to help is to [...]

2019-02-26T08:19:47-08:00February 26th, 2019|

Active surveillance nearly tripled in men with low-risk prostate disease

Many men with low-risk prostate cancer who most likely previously would have undergone immediate surgery or radiation are now adopting a more conservative "active surveillance" strategy, according to an analysis of a new federal database by scientists from Dana-Farber Cancer Institute. The use of active surveillance increased from 14.5 percent to 42.1 percent of men with low-risk prostate cancer between 2010 and 2015, said the researchers, led by Brandon Mahal, MD, from the department of radiation oncology at Dana-Farber/Brigham and Women's Cancer Center who led the study published by JAMA. During that same period, the percentage of men undergoing radical prostatectomy (removal of the prostate gland) declined from 47.4 percent to 31.3 percent. The use of radiotherapy for low-risk disease dropped from 38.0 percent [...]

2019-02-12T11:42:12-08:00February 12th, 2019|

HIFU: Creating A New Prostate Cancer Treatment Paradigm

Utilizing focused ultrasound, the Sonablate system is a minimally invasive robotic device that delivers precise and focused ablative energy. This new surgical option for prostate cancer gives surgeons minimally invasive options for destroying unhealthy tissue with thermal ablation throughout the body. This is a new treatment paradigm that combines elements from radiology, needle ablation and surgery to effectively ablate targeted tissue with minimal impact on a patient's quality of life. Reduced side effect profiles Reduced procedure time Tissue sparing intervention across specialties More favorable outcomes via "non-cutting" intervention. Imaging and feedback tools provide live results from targeted area(s) Increases the number of patients appropriate for surgical intervention Reduces costs associated with surgical intervention Minimally Invasive Real-time Imaging Radiation Free Don't wait until it's too late. [...]

2019-02-05T08:55:07-08:00February 5th, 2019|

Prostate Cancer News: PSA screening significantly reduces the risk for death

After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. These findings suggest that current guidelines recommending against routine PSA-based screening may be revised. However, questions remain about how to implement screening so that the benefits outweigh the potential harms of over-diagnosis and overtreatment. The findings are published in Annals of Internal Medicine. Current guidelines from the United States Preventive Services Task Force (USPSTF) recommend against prostate-specific antigen (PSA) screening for prostate cancer because the evidence for the test showed very low probability that it would [...]

2019-01-16T09:41:10-08:00January 16th, 2019|

Fewer men are being screened, diagnosed, and treated for prostate cancer

A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. There is considerable debate surrounding the value of prostate cancer screening with prostate-specific antigen (PSA) testing, and the 2012 United States Preventive Services Task Force (USPSTF) recommendation against PSA testing lies at the center of this debate. This recommendation was made in part due to the potential harms -- such as erectile dysfunction and urinary incontinence -- associated with the treatment of clinically insignificant prostate cancer with radical prostatectomy or radiation. To examine the [...]

2019-01-15T11:04:18-08:00January 15th, 2019|